

NEWS RELEASE

iX Biopharma's Xativa™, the world's first freeze-dried sublingual medicinal cannabis wafer, records robust uptake from initial production runs in Australia

Singapore, 30 June 2020 – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce robust uptake of Xativa™ following its launch in Australia at the end of April 2020. Its initial production runs of approximately 1700 boxes of Xativa™, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold.

Doctors and patients have responded enthusiastically to the Xativa™ launch. They acknowledge that Xativa™ differentiates from other commonly available products (mainly flowers, oils and oral capsules) as it has valuable features such as fixed unit dosing, improved speed and level of absorption, as well as predictability of effect. Xativa™ is also expected to be a superior alternative for certain population segments including the young and senior citizens, as it is easy to use and avoids the need to swallow capsules or ingest oils which may be more difficult to tolerate. The launch was covered by an Australian national news network, [Nine News](#), which helped to raise awareness of the benefits of Xativa™ and the WaferiX sublingual delivery technology.

Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: “*We are very encouraged by the interest and demand garnered for true sublingual cannabis wafers. The early enthusiastic response from both patients and doctors gives us confidence that WaferiX™ based sublingual cannabis wafers provides a strong value proposition when compared to existing products in the market.*”

CBD, one of the primary non-psychoactive compounds found in the cannabis plant, has attracted growing interest in recent times due to its safety and effectiveness in treating a vast spectrum of human health issues. While its medicinal benefits are clear, most delivery forms available today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability to truly provide an effective therapeutic effect for users. Leveraging on iX Biopharma's novel and patented WaferiX™ technology, the Group has developed Xativa™ to address this gap in the market.

Manufactured via iX Biopharma's proprietary freeze-drying technique, the WaferiX™ matrix holding the active CBD molecules is designed to transport drug actives rapidly across the sublingual membrane into the blood vessels for rapid absorption and faster therapeutic action. Furthermore, Xativa™ offers a fixed unit dose that is familiar to physicians, facilitating standardised prescription and precise dosing.

For more information on Xativa™, please refer to the link below:

[\[http://www.ixbiopharma.com/xativa\]](http://www.ixbiopharma.com/xativa)

- The End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Contact for media:

Dr Janakan Krishnarajah

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

Investor Relations:

Kamal Samuel/James Bywater/Jonathan Wee

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.
